{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:41:32Z","timestamp":1790444492516,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pure red cell aplasia (PRCA) is a rare hematological disorder characterized by erythroid hypoplasia and maturation arrest in the bone marrow. We present a case of acquired PRCA secondary to smoldering multiple myeloma (SMM), initially presenting as severe anemia requiring multiple blood transfusions. This case highlights the diagnostic dilemma at presentation as well as the therapeutic challenges in treating PRCA secondary to SMM. Here we discuss the appropriate workup and identify a potential option for managing these patients with subcutaenous daratumumab.<\/jats:p>","DOI":"10.1007\/s00277-025-06218-z","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T23:26:58Z","timestamp":1739921218000},"page":"2027-2034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rare case of pure red cell aplasia secondary to smoldering multiple myeloma successfully treated with daratumumab \u2013 case report and review of the literature"],"prefix":"10.1007","volume":"104","author":[{"given":"Malak","family":"Alharbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawyer","family":"Bawek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Wen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"3","key":"6218_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.amjms.2023.06.009","volume":"366","author":"RT Means Jr","year":"2023","unstructured":"Means RT Jr. (2023) Pure red cell aplasia: the second hundred years. Am J Med Sci 366(3):160\u2013166. https:\/\/doi.org\/10.1016\/j.amjms.2023.06.009","journal-title":"Am J Med Sci"},{"issue":"21","key":"6218_CR2","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","volume":"128","author":"RT Means Jr","year":"2016","unstructured":"Means RT Jr (2016) Pure red cell aplasia. Blood 128(21):2504\u20132509. https:\/\/doi.org\/10.1182\/blood-2016-05-717140","journal-title":"Blood"},{"key":"6218_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lrr.2018.06.005","volume":"10","author":"T Ito","year":"2018","unstructured":"Ito T, Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Konishi A, Hotta M, Yoshimura H, Ishii K, Nomura S (2018) Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide. Leuk Res Rep 10:4\u20136. https:\/\/doi.org\/10.1016\/j.lrr.2018.06.005","journal-title":"Leuk Res Rep"},{"issue":"10","key":"6218_CR4","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00277-013-1721-5","volume":"92","author":"CC So","year":"2013","unstructured":"So CC, Choi WW, Kwong YL (2013) Pure red cell aplasia associated with CD20\u2009+\u2009myeloma: complete remission with rituximab. Ann Hematol 92(10):1425\u20131426. https:\/\/doi.org\/10.1007\/s00277-013-1721-5","journal-title":"Ann Hematol"},{"issue":"1","key":"6218_CR5","first-page":"1498","volume":"8","author":"Y Lv","year":"2015","unstructured":"Lv Y, Qian W (2015) Treatment of pure red cell aplasia associated with multiple myeloma with biclonal gammopathy using cyclosporine A: a case report. Int J Clin Exp Med 8(1):1498\u20131500","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"6218_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bjh.14012","volume":"173","author":"N Korde","year":"2016","unstructured":"Korde N, Zhang Y, Loeliger K, Poon A, Simakova O, Zingone A, Costello R, Childs R, Noel P, Silver S, Kwok M, Mo C, Young N, Landgren O, Sloand E, Maric I (2016) Monoclonal gammopathy-associated pure red cell aplasia. Br J Haematol 173(6):876\u2013883. https:\/\/doi.org\/10.1111\/bjh.14012","journal-title":"Br J Haematol"},{"issue":"4","key":"6218_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/s0145-2126(97)00028-3","volume":"21","author":"J Orchard","year":"1997","unstructured":"Orchard J, Myint H, Hamblin TJ (1997) A patient with myeloma who still has pure red cell aplasia despite the most intensive immune modulation. Leuk Res 21(4):353\u2013354. https:\/\/doi.org\/10.1016\/s0145-2126(97)00028-3","journal-title":"Leuk Res"},{"issue":"9","key":"6218_CR8","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1080\/10428194.2019.1574007","volume":"60","author":"AS Eziokwu","year":"2019","unstructured":"Eziokwu AS, Silver B, Samaras C (2019) Acquired red cell aplasia associated with monoclonal gammopathy of undetermined significance. Leuk Lymphoma 60(9):2337\u20132339. https:\/\/doi.org\/10.1080\/10428194.2019.1574007","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6218_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.7754\/Clin.Lab.2016.160730","volume":"63","author":"H Gu","year":"2017","unstructured":"Gu H, Lee WI, Jeon Y, Kang SY, Kim MH, Park TS (2017) Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of undetermined significance and literature review. Clin Lab 63(2):373\u2013378. https:\/\/doi.org\/10.7754\/Clin.Lab.2016.160730","journal-title":"Clin Lab"},{"issue":"4","key":"6218_CR10","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/jha2.964","volume":"5","author":"CS Michel","year":"2024","unstructured":"Michel CS, Fehr EM, Nolte H, Beck J, Kreft A, Rauschkolb-Olk KT, Jacobi B, Theobald M, Munder M (2024) Effective treatment of refractory monoclonal gammopathy-associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone. EJHaem 5(4):838\u2013841. https:\/\/doi.org\/10.1002\/jha2.964","journal-title":"EJHaem"},{"issue":"9","key":"6218_CR11","first-page":"578","volume":"12","author":"D Kazandjian","year":"2014","unstructured":"Kazandjian D, Mailankody S, Korde N, Landgren O (2014) Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. Clin Adv Hematol Oncol 12(9):578\u2013587","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"6218_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, W\u00e4sch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A (2014) European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99(2):232\u2013242. https:\/\/doi.org\/10.3324\/haematol.2013.099358","journal-title":"Haematologica"},{"issue":"9","key":"6218_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV, Kumar S, Lonial S, Mateos MV (2022) Smoldering multiple myeloma current treatment algorithms. Blood Cancer J 12(9):129. https:\/\/doi.org\/10.1038\/s41408-022-00719-0","journal-title":"Blood Cancer J"},{"issue":"1","key":"6218_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","volume":"9","author":"L Sanchez","year":"2016","unstructured":"Sanchez L, Wang Y, Siegel DS, Wang ML (2016) Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 9(1):51. https:\/\/doi.org\/10.1186\/s13045-016-0283-0","journal-title":"J Hematol Oncol"},{"issue":"11","key":"6218_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","volume":"22","author":"V Bhatnagar","year":"2017","unstructured":"Bhatnagar V, Gormley NJ, Luo L, Shen YL, Sridhara R, Subramaniam S, Shen G, Ma L, Shord S, Goldberg KB, Farrell AT, McKee AE, Pazdur R (2017) FDA approval Summary: Daratumumab for treatment of multiple myeloma after one prior therapy. Oncologist 22(11):1347\u20131353. https:\/\/doi.org\/10.1634\/theoncologist.2017-0229","journal-title":"Oncologist"},{"issue":"11","key":"6218_CR16","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/s1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O\u2019Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, Usmani SZ (2021) Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22(11):1582\u20131596. https:\/\/doi.org\/10.1016\/s1470-2045(21)00466-6","journal-title":"Lancet Oncol"},{"issue":"4","key":"6218_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk N, Katodritou E, Schjesvold F, Sureda Balari A, Rosi\u00f1ol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Blad\u00e9 J, Moreau P (2024) Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 390(4):301\u2013313. https:\/\/doi.org\/10.1056\/NEJMoa2312054","journal-title":"N Engl J Med"},{"issue":"6","key":"6218_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J (2018) Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma. N Engl J Med 378(6):518\u2013528. https:\/\/doi.org\/10.1056\/NEJMoa1714678","journal-title":"N Engl J Med"},{"key":"6218_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409029","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV (2024) Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2409029","journal-title":"N Engl J Med"},{"key":"6218_CR20","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1182\/blood-2024-209251","volume":"144","author":"VH Jimenez-Zepeda","year":"2024","unstructured":"Jimenez-Zepeda VH, Sandhu I, Chu MP, Rankin K, McCurdy A, Sapru H, Cipkar C, Koo E, Patrick B, Albert S, Henia M, McCudden C, Visram A (2024) Incidence and prevalence of clinically detected smoldering multiple myeloma among the General Population. Blood 144:1912. https:\/\/doi.org\/10.1182\/blood-2024-209251","journal-title":"Blood"},{"issue":"10","key":"6218_CR21","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1038\/bcj.2016.100","volume":"6","author":"A Ravindran","year":"2016","unstructured":"Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, Hashmi SK, Marshall AL, Ashrani AA, Dispenzieri A, Kyle RA, Rajkumar SV, Go RS (2016) Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J 6(10):e486. https:\/\/doi.org\/10.1038\/bcj.2016.100","journal-title":"Blood Cancer J"},{"issue":"1","key":"6218_CR22","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1038\/s41598-021-81890-5","volume":"11","author":"N Fujishima","year":"2021","unstructured":"Fujishima N, Kohmaru J, Koyota S, Kuba K, Saga T, Omokawa A, Moritoki Y, Ueki S, Ishida F, Nakao S, Matsuda A, Ohta A, Tohyama K, Yamasaki H, Usuki K, Nakashima Y, Sato S, Miyazaki Y, Nannya Y, Ogawa S, Sawada K, Mitani K, Hirokawa M (2021) Clonal hematopoiesis in adult pure red cell aplasia. Sci Rep 11(1):2253. https:\/\/doi.org\/10.1038\/s41598-021-81890-5","journal-title":"Sci Rep"},{"issue":"1","key":"6218_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/16078454.2021.1929694","volume":"26","author":"H Wang","year":"2021","unstructured":"Wang H, Niu H, Zhang T, Xing L, Shao Z, Fu R (2021) Low- and intermediate-risk myelodysplastic syndrome with pure red cell aplasia. Hematology 26(1):444\u2013446. https:\/\/doi.org\/10.1080\/16078454.2021.1929694","journal-title":"Hematology"},{"key":"6218_CR24","doi-asserted-by":"publisher","unstructured":"Zhu Y, Wang Z, Li Y, Peng H, Liu J, Zhang J, Xiao X (2023) The role of CREBBP\/EP300 and its therapeutic implications in hematological malignancies. Cancers (Basel) 15(4). https:\/\/doi.org\/10.3390\/cancers15041219","DOI":"10.3390\/cancers15041219"},{"key":"6218_CR25","unstructured":"ClinVar NCfBI, National Center for Biotechnology Information (2025) ClinVar. VCV000975520.12. https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/VCV000975520.12 Accessed Jan. 6 2025"},{"issue":"1","key":"6218_CR26","doi-asserted-by":"publisher","first-page":"20508","DOI":"10.1038\/s41598-020-77450-y","volume":"10","author":"L Liu","year":"2020","unstructured":"Liu L, Yu Z, Cheng H, Mao X, Sui W, Deng S, Wei X, Lv J, Du C, Xu J, Huang W, Xia S, An G, Zhou W, Ma X, Cheng T, Qiu L, Hao M (2020) Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Sci Rep 10(1):20508. https:\/\/doi.org\/10.1038\/s41598-020-77450-y","journal-title":"Sci Rep"},{"issue":"4","key":"6218_CR27","first-page":"233","volume":"2","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Pohl G, Osterborg A (2004) Anemia in multiple myeloma. Clin Adv Hematol Oncol 2(4):233\u2013241","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"6218_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/j.seminhematol.2010.11.004","volume":"48","author":"N Korde","year":"2011","unstructured":"Korde N, Maric I (2011) Myelomagenesis: capturing early microenvironment changes. Semin Hematol 48(1):13\u201321. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.11.004","journal-title":"Semin Hematol"},{"issue":"11","key":"6218_CR29","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1158\/1078-0432.Ccr-07-4153","volume":"14","author":"S Sharma","year":"2008","unstructured":"Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, Ganz T, Lichtenstein A (2008) Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14(11):3262\u20133267. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-4153","journal-title":"Clin Cancer Res"},{"issue":"9","key":"6218_CR30","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/jci20945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271\u20131276. https:\/\/doi.org\/10.1172\/jci20945","journal-title":"J Clin Invest"},{"issue":"18","key":"6218_CR31","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2010-03-274571","volume":"116","author":"K Maes","year":"2010","unstructured":"Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys L, Rivera S, Vanderkerken K, Lichtenstein A, Ganz T (2010) In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 116(18):3635\u20133644. https:\/\/doi.org\/10.1182\/blood-2010-03-274571","journal-title":"Blood"},{"issue":"12","key":"6218_CR32","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1182\/blood.V81.12.3357.3357","volume":"81","author":"H Hata","year":"1993","unstructured":"Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J (1993) Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 81(12):3357\u20133364. https:\/\/doi.org\/10.1182\/blood.V81.12.3357.3357","journal-title":"Blood"},{"issue":"2","key":"6218_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.v97.2.483","volume":"97","author":"MA Frassanito","year":"2001","unstructured":"Frassanito MA, Cusmai A, Iodice G, Dammacco F (2001) Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97(2):483\u2013489. https:\/\/doi.org\/10.1182\/blood.v97.2.483","journal-title":"Blood"},{"issue":"4","key":"6218_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/bjh.17463","volume":"193","author":"T Longval","year":"2021","unstructured":"Longval T, Galimard JE, Lepr\u00eatre AC, Suarez F, Amiranoff D, Cazaux M, Kaphan E, Michonneau D, Dhedin N, Coman T, Nguyen Quoc S, de Peffault R, Resche-Rigon M, de Sicre F (2021) Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol 193(4):814\u2013826. https:\/\/doi.org\/10.1111\/bjh.17463","journal-title":"Br J Haematol"},{"key":"6218_CR35","doi-asserted-by":"publisher","unstructured":"Nauffal M, Eng S, Lin A, Chan A, Mazzerella K, Giralt S, Perales MA, Gyurkocza B (2024) Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation. Case Rep Hematol 2024:5790011. https:\/\/doi.org\/10.1155\/2024\/5790011","DOI":"10.1155\/2024\/5790011"},{"issue":"6","key":"6218_CR36","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1159\/000515257","volume":"144","author":"I Henig","year":"2021","unstructured":"Henig I, Yehudai-Ofir D, Zohar Y, Zuckerman T (2021) Pure red cell aplasia following ABO-Mismatched allogeneic hematopoietic stem cell transplantation: resolution with Daratumumab Treatment. Acta Haematol 144(6):683\u2013687. https:\/\/doi.org\/10.1159\/000515257","journal-title":"Acta Haematol"},{"issue":"2","key":"6218_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/ejh.13343","volume":"104","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Alahmari A, Lipton JH (2020) Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol 104(2):145\u2013147. https:\/\/doi.org\/10.1111\/ejh.13343","journal-title":"Eur J Haematol"},{"issue":"19","key":"6218_CR38","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","volume":"379","author":"CI Chapuy","year":"2018","unstructured":"Chapuy CI, Kaufman RM, Alyea EP, Connors JM (2018) Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med 379(19):1846\u20131850. https:\/\/doi.org\/10.1056\/NEJMoa1807438","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06218-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06218-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06218-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:09:55Z","timestamp":1745561395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06218-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6218"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06218-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"was obtained from the patient for the use of the case and for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}